3D-printed brachytherapy in patients with cervical cancer: improving efficacy and safety outcomes

Radiation Oncology

Table 3 Comparison of effective target areas and organ damage in radiotherapy for small tumours

Variables	3D radiotherapy	Freehand implant radiotherapy	t	P-value
Variables	(n = 19)	(n = 20)	t	P-value
Target area dose
CTV-D95 (Gy, \(\:\stackrel{-}{x}\)±s)	53.39 ± 0.93	51.19 ± 2.88	-3.242	0.004**
CTV-D98 (Gy, \(\:\stackrel{-}{x}\)±s)	47.99 ± 1.30	44.66 ± 3.22	-4.276	< 0.001***
CTV-D100 (Gy, \(\:\stackrel{-}{x}\)±s)	36.64 ± 2.60	32.74 ± 4.30	-3.451	0.002**
Dose-volume ratio
CTV-v100 (%, \(\:\stackrel{-}{x}\)±s)	80.18 ± 7.08	89.10 ± 8.33	3.599	< 0.001***
CTV-v150 (%, \(\:\stackrel{-}{x}\)±s)	62.26 ± 2.57	64.50 ± 5.35	1.681	0.104
CTV-v200 (%, \(\:\stackrel{-}{x}\)±s)	44.56 ± 3.44	45.32 ± 6.14	0.483	0.633
Organ-damaging
Bladder irradiation dose D1CC (Gy, \(\:\stackrel{-}{x}\)±s)	43.71 ± 10.38	55.39 ± 12.83	3.117	0.004**
Bladder irradiation dose D2CC (Gy, \(\:\stackrel{-}{x}\)±s)	38.84 ± 8.87	48.72 ± 11.71	2.960	0.005**
Rectal irradiation dose D1CC (Gy, \(\:\stackrel{-}{x}\)±s)	34.62 ± 16.39	51.55 ± 15.18	3.349	0.002**
Rectal irradiation dose D2CC (Gy, \(\:\stackrel{-}{x}\)±s)	28.77 ± 14.59	44.28 ± 12.59	3.560	0.001***

Note Data are presented as mean ± SD. Abbreviations 3D radiotherapy, IMRT combined with 3D postloading radiotherapy group; Freehand implant radiotherapy, IMRT combined with freehand implantation of the posterior loading radiotherapy group; CTV, Clinical Target Volume; D1CC, Dose corresponding to the volume of the largest portion of the highest dose received; D2CC, Dose corresponding to the volume of the largest part of the second highest dose received

ISSN: 1748-717X